Pfizer Intrinsic Value
Pfizer (PFIZER) median intrinsic value is ₹2300.00 from 10 valuation models (range ₹1201–₹3535), vs current price ₹4002.40 — -42.5% downside (Trading Above Calculated Value), margin of safety -74.0%. For current market price and key ratios, visit Pfizer share price screener.
PFIZER Valuation Methods Summary — DCF, Graham Number & P/E
Pfizer intrinsic value across 10 models vs current price ₹4002.40 — upside/downside and value range per method. See PFIZER P/B ratio to compare market price against book value per share.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3535.40 | ₹2828.32 - ₹4242.48 | -11.7% | EPS: ₹160.70, Sector P/E: 22x |
| Book Value Method | asset | ₹1827.39 | ₹1644.65 - ₹2010.13 | -54.3% | Book Value/Share: ₹913.70, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1200.72 | ₹1080.65 - ₹1320.79 | -70.0% | Revenue/Share: ₹596.52, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2300.00 | ₹2070.00 - ₹2530.00 | -42.5% | EBITDA: ₹1058.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2347.20 | ₹1877.76 - ₹2816.64 | -41.4% | CF Growth: 9.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹1200.72 | ₹1080.65 - ₹1320.79 | -70.0% | EPS Growth: 4.2%, Fair P/E: 3.4x |
| Growth Adjusted P/E | growth | ₹2435.70 | ₹2192.13 - ₹2679.27 | -39.1% | Revenue Growth: 2.1%, Adj P/E: 15.2x |
| ROE Based Valuation | profitability | ₹2236.96 | ₹2013.26 - ₹2460.66 | -44.1% | ROE: 17.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1817.61 | ₹1635.85 - ₹1999.37 | -54.6% | EPS: ₹160.70, BVPS: ₹913.70 |
| Dividend Yield Method | dividend | ₹3000.00 | ₹2700.00 - ₹3300.00 | -25.0% | DPS: ₹75.00, Target Yield: 2.5% |
PFIZER Intrinsic Value vs Market Price — All Valuation Models
Pfizer fair value range ₹1201–₹3535 vs current market price ₹4002.40 across 10 valuation models. Check PFIZER market capitalization to track the company's total market size over time.
PFIZER Intrinsic Value Analysis — Undervalued or Overvalued?
Pfizer median intrinsic value ₹2300.00, current price ₹4002.40 — Trading Above Calculated Value by 42.5%, margin of safety -74.0%.
What is the intrinsic value of PFIZER?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Pfizer (PFIZER) is ₹2300.00 (median value). With the current market price of ₹4002.40, this represents a -42.5% variance from our estimated fair value.
The valuation range spans from ₹1200.72 to ₹3535.40, indicating ₹1200.72 - ₹3535.40.
Is PFIZER undervalued or overvalued?
Based on our multi-method analysis, Pfizer (PFIZER) appears to be trading above calculated value by approximately 42.5%.
PFIZER Financial Health — Key Ratios vs Industry Benchmarks
Pfizer financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 41.34 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PFIZER Cash Flow Quality — Operating & Free Cash Flow
Pfizer operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹968 Cr | ₹687 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹660 Cr | ₹625 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹257 Cr | ₹257 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹356 Cr | ₹338 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹667 Cr | ₹380 Cr | Positive Free Cash Flow | 8/10 |